KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
69 hedge funds and large institutions have $120M invested in KalVista Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 22 reducing their positions, and 12 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 22
10.78% more ownership
Funds ownership: 76.96% → 87.73% (+11%)
5% less funds holding
Funds holding: 73 → 69 (-4)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
51% less capital invested
Capital invested by funds: $244M → $120M (-$125M)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$19.9M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$9.91M |
| 3 |
O
OrbiMed
New York
|
+$3.51M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.04M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$2.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$3.56M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.92M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.35M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
-$953K |
| 5 |
DAM
DLD Asset Management
New York
|
-$891K |
KALV Hedge Fund Activity: Q1 2020 in Review
69 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2020, worth a combined $120M — down 51% from $244M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of KALV and 10 opened new positions — a net loss of 2 holders — while 22 trimmed existing stakes and 25 added.
The largest buyer was Vivo Capital, opening a new position worth an estimated $19.9M. The largest seller was Boxer Capital, exiting entirely with an estimated $3.56M sold.
- 69 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2020, down from 73 in Q4 2019.
- Funds reported $120M of KalVista Pharmaceuticals stock for Q1 2020, down 51% quarter-over-quarter.
- 10 funds opened new KalVista Pharmaceuticals positions in Q1 2020 and 12 closed out, a net change of -2 holders.
- The largest KalVista Pharmaceuticals buyer in Q1 2020 was Vivo Capital, an estimated $19.9M added.
- The largest KalVista Pharmaceuticals seller in Q1 2020 was Boxer Capital, an estimated $3.56M sold.
Based on aggregated 13F filings for Q1 2020.